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Background: Esophageal squamous cell carcinoma (ESCC) is an aggressive tumor with dismal prognosis and high
incidence and mortality in Kazakh population. MiR-34a, a direct p53 target gene, possesses tumor-suppressive properties
as they mediate apoptosis, cell cycle arrest, and senescence. The reduced expression of miR-34a by methylation in various
cancers has been reported.
Methods: To determine whether aberrant miR-34a methylation occurs in esophageal cancer, the DNA methylation of 23
CpGs sites in the miR-34a promoter was quantitatively analyzed in relation to the translation initiation site by MALDI -TOF
mass spectrometry in 59 ESCC tissues and 34 normal tissues from the Kazakh population. Real-time PCR was used to
detect the inhibition of miR-34a expression levels and to evaluate their association with methylation.
Results: We found that miR-34a is more frequently methylated in ESCC (0.133 ± 0.040) than in controls (0.066 ± 0.045,
P < 0.01). A nearly two-fold increase in miR-34a expression for the hypomethylated promoter was found in normal
esophageal tissues than ESCC with hypermethylation (P <0.0001), pointing to a negative relationship between miR-34a
CpG sites methylation and expression(r = −0.594, P = 0.042). The hypermethylation of miR-34a CpG_8.9 was associated
with the advanced UICC stage III/IV of the esophageal cancers, and the hypermethylation of CpG_8.9 and CpG_5 of
miR-34a was significantly correlated with lymph node metastasis.
Conclusions: Our findings suggest that miR-34a is involved in the etiology of ESCC and that hypermethylated miR-34a
is a potential biomarker for ESCC diagnosis and prognosis. Moreover, targeting miR-34a methylation by demethylating
agents may offer a novel strategy for anticancer therapy of ESCC.
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Esophageal squamous cell carcinoma (ESCC) is one of
the most malignant cancers worldwide, ranking as the
fourth most common cause of cancer-related deaths
in China [1]. Compared with other ethnic populations
in China and those in Xinjiang, where most Chinese* Correspondence: cyz0515@sina.com; lifeng7855@126.com
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unless otherwise stated.Kazakhs reside, the Kazakh population is characterized by
higher incidence and mortality (90-150/100 000, age
standardized) of ESCC than those in the general population
of China [2-4]. Genetic defects, including the mutation or
amplification of oncogenes and the inhibition of tumor-
suppressor genes, such as EGFR, KRAS, pRb, and cyclin
D1 mutations [5-8], are involved in the carcinogenesis of
ESCC. In addition, it is well established that p53 mutation
is the most common genetic alteration in 60.6% of ESCC
[9]. By contrast, gene methylation is an alternative
mechanism of gene inactivation that occurs early tumor
progression and thus alters gene expression without
changing the DNA sequence [10-12]. Similar to genetic. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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is stably inherited to the next cell generation and may
therefore allow the clonal expansion of a cell population
with a selective advantage during tumor progression.
Various tumor-suppressor genes that regulate apoptosis,
the cell cycle, and cell signaling are aberrantly methylated
in ESCC [12-14].Given these observations, uncovering the
molecular pathogenesis of Kazakh ESCC, especially the
detection of aberrant CpG methylation, is therefore likely
to provide new approaches to the prevention, diagnosis
and treatment of ESCC.
MicroRNA (miRNA), a class of small regulatory RNA
molecules, acts as tumor suppressors and oncogenes by
negatively regulating their mRNA targets in a sequence-
specific manner through post-transcriptional repression
and influencing the proliferation and cell cycle progression,
apoptosis, invasion and metastasis of cancer [10]. Wide-
spread miRNA is dysregulated in various human malig-
nancies by changes in DNA copy number and epigenetic
inactivation, although their exact functions during car-
cinogenesis are still being examined [15-17]. In esophageal
cancer, the reduced expression of miR-143 or the overex-
pression of miR-7 is reportedly correlated with the depth
of invasion and lymph node metastasis of ESCC [18].
Among the types of miRNAs, the miR-34a gene, which
resides in chromosome 1q36.22 and belongs to the miR-
34 family, reportedly is directly regulated by the p53
transcription factor [19,20]. The miR-34a downregulates
numerous important regulatory proteins of cell cycle
progression and apoptosis, such as E2F3, c-MYC, Bcl2,
c-MET, and CDK4/6, suggesting that miR-34a itself may
mediate tumor suppression [21]. The reduced or absent
expression of miR-34a was reported in 110 cancer cells
lines, such as breast, lung, colon, kidney, melanoma,
bladder, pancreatic carcinoma, lymphoma, and myeloma
and cell lines, and two different types of primary cancers
(melanoma and primary neuroblastoma samples) because
of the aberrant CpG methylation of its promoter [22-24].
However, only one study have reported that the miR-34a
was silenced in ESCC cell lines and re-expression miR-34a
can inhibit the ESCC proliferation by reducing the C-met
and Cyclin D1 expression [24], yet the correlation between
downregulation/loss of miR-34a expression and promoter
methylation in ESCC was not clean, especially in the
Kazakh population.
Given that aberrant DNA methylation is an important
mechanism for gene transcription and protein expression
silencing, in the present study, we accordingly therefore
hypothesized whether epigenetic modifications indir-
ectly modulate miR-34a expression by silencing or acti-
vating miR-34a genes in Kazakh ESCC patients. To
address this problem, using the matrix-assisted laser de-
sorption ionization time-of-flight mass spectrometry
(MALDI-TOF MS) approach, we quantitatively evaluatedthe individual CpG unit methylation in 318 base pairs re-
gions in length (proximal region encompassing the tran-
scription start site and the p53 binding sites) containing
23 CpG sites within 15 CpG units at the miR-34a pro-
moter regions with a total of 93 Kazakh subjects. The rela-
tionship between the promoter methylation and gene
expression of miR-34a in patients with and without
ESCC in additional samples was also examined to ex-
plore the mechanism of the development of Kazakh
ESCC. The promoter hypermethylation of the miR-34a
gene was correlated with the downregulation of mRNA
expression in Kazakh ESCC, providing insight into the
molecular mechanism of Kazakh esophageal cancer and
the pathogenesis of the cancer in relation to the function
of the hypermethylation of the miR-34a promoter.
Materials and methods
Patients and tissue samples
Fifty-nine esophageal tissues from Kazakh patients diag-
nosed with histologically confirmed ESCC were randomly
collected by multistage cluster sampling. All patients
were recruited from the First Affiliated Hospital of
Shihezi University and the People’s Hospital of Xinjiang
Uygur Autonomous Region between 1984 and 2011.
No restrictions regarding age, sex, or disease stage were
set. Patients who had undergone surgery (other than
diagnostic biopsies), chemotherapy, or radiation ther-
apy before recruitment or any blood transfusion in the
preceding six months were excluded. All samples were
surgically resected, fixed in 10% buffered formalin,
routinely processed, and embedded in paraffin. We
gathered data on clinic-pathological variables, such as
tumor site, invasion depth, and distant metastasis from
the medical records of the patients. The differentiation
grade, TNM stage, and lymph node status were classi-
fied according to the UICC/AJCC TNM classification
(seventh edition). For comparison, 34 samples of nor-
mal esophageal tissue were obtained from materials
surgically resected from 34 patients without any primary
esophageal tumor.
In this study, various clinic-pathological characteristics of
Kazakh ESCC cases and controls were investigated as fol-
lows (Additional file 1: Table S1). The age was 55.1 ± 8.26
(mean ± SD) years for the cancer samples and 44.7 ± 7.8
(mean ± SD) years for the normal sample (P =0.54). There
were 32 (54.2%) males and 27 (45.8%) females in the case
group and 19 (55.9%) males and 15 (44.1%) females in the
control group (P = 0.87). The cases included 14 (23.7%)
well-differentiated patients (group G1), 30 (50.9%) moder-
ately differentiated patients (G2), and 15 (25.4%) poorly
differentiated patients (G3). Of the 59 ESCC cases, 32
(54.2%) were classified as stage I/II and 27 (45.8%) as stage
III/IV. Thirty-three of the patients presented with lymph
node metastases.
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Committee of Shihezi University School of Medicine,
P. R. China. Written informed consent was obtained
from all of the patients. All specimens were handled
and made anonymous according to the ethical and
legal standards.
DNA isolation and bisulfate conversion
DNA was isolated from 10 tissue sections of 10 μm
thickness by proteinase K digestion and a tissue DNA
extraction kit (Qiagen Inc., Valencia, CA, USA) according
to the manufacturer’s protocol. As an internal control, all
purified genomic DNA samples were successfully tested
by polymerase chain reaction (PCR) with human β-actin
primers For: 5′-CAGACACCATGGTGCACCTGAC-3′
and Rev: 5′-CCAATAGGCAGAGAGAGTCAGTG-3′,
indicating that the suitable quality and quantity of DNA
can be used to detect the profile of miR-34a methylation.
Genomic DNA was stored at −20°C until use as a tem-
plate for each PCR reaction. The genomic DNA was
treated with bisulfite through an EZ DNA Methylation
KitTM according to the manufacturer’s instructions
(Zymo Research, Orange, CA, USA) (Catalog No. D5001).
This treatment combines bisulfate conversion and DNA
clean-up. The converted DNA was measured by an ND-
1000 spectrophotometer (NanoDrop Technologies, Inc.,
Wilmington, DE, USA).
Quantitative analysis of DNA methylation
The sequence of the CpG island was identified by the
UCSC genome browser (http://genome.ucsc.edu/). Given
that the genomic region upstream the p53 binding site
in the miR-34a gene revealed a prominent CpG island,
we selected the area with proximal promoter activity in
previous experiments [22]. The analyzed region and the
CpG sites of the miR-34a promoter are shown in Figure 1.
We designed primer sets for the methylation analysis of
the miR-34a promoter region by EpiDesigner software
(http://epidesigner.com; Table 1). For each reverse primer,
an additional T7 promoter tag was added for in vivo
transcription, and a 10-mer tag was added to the forward
primer to adjust for differences in melting temperature.
The DNA methylation of miR-34a was quantitatively
analyzed by the MassARRAY platform (SEQUENOM)
as previously described [25]. The 5 μl PCR mixture con-
tained 10 ng of bisulfite-treated DNA, 25 mM dNTP,
0.2 U of Hot Start TaqDNA polymerase (Sequenom,
Sequenom Inc., San Diego, CA, USA), and a 1 μM mix-
ture of forward and reverse primers. The cycles included
pre-heating at 94°C for 4 min, followed by incubation for
45 cycles of 94°C for 20 s, 62°C for 30 s, and 72°C for 60 s
and then by incubation at 72°C for 3 min. Two microliters
of a shrimp alkaline phosphatase (SAP) mix containing
1.7 μl of H2O and 0.3 μl (1.7 U) of SAP (Sequenom) wasadded to digest redundant dNTPs with the following pro-
gram: 37°C for 20 min, 85°C for 5 min, and 4°C thereafter.
After the SAP treatment, unincorporated dNTPs were
dephosphorylated by adding 2 ml of premix including
0.3 U of SAP (Sequenom). The reaction mixture was
incubated at 37°C for 40 min, and the SAP was heat-
inactivated for 5 min at 85°C and was then maintained
at 4°C. Five microliters of T Cleavage Transcription/
RNase Cocktail including 0.89 μl of 5× T7 polymerase
buffer, 0.24 μl of T cleavage mix, 3.14 mM dithiothreitol,
22 U of T7 RNA and DNA polymerase, 0.09 mg/ml of
RNase A, and 2 μl of the product of the PCR/SAP reactions
was mixed and incubated under the following conditions:
37°C for 3 h of in vitro transcription and RNase A diges-
tion. Fifteen nanoliters of cleavage reaction was then
robotically dispensed (by a nanodispenser) onto silicon
chips preloaded with a matrix (SpectroCHIP; SEQUENOM,
San Diego). Mass spectra were collected by MassARRAY
Compact MALDI-TOF (SEQUENOM), and the methyla-
tion proportions of the spectra were generated by Epityper
1.0 software (SEQUENOM, San Diego). All the experi-
ments were performed in triplicate. Inapplicable readings
and their corresponding sites were eliminated from analysis.
The methylation level was expressed as the percentage of
methylated cytosines over the total number of methylated
and unmethylated cytosines.
cDNA synthesis and real-time PCR
Real-time PCR was conducted in two steps as previously
described. RNA was extracted from ESCC cells with the
RNeasy Mini Kit (Qiagen, Hilden, Germany). cDNA was
amplified with specific primer sets: MiR-34a (Hs_miR-
34a_1 miScript Primer Assay, MS00003318) and RNU6
(Hs_RNU6-2_1 miScript Primer Assay, MS00033740) in a
Stratagene Mx-3000P real-time thermocycler (Stratagene,
La Jolla, CA). Quantitative real-time PCR was conducted
with a SYBR green PCR Master Mix (Qiagen, Hilden,
Germany) containing ROX as a reference dye. Data were
normalized for RNU6 (housekeeping gene) expression
by the comparative threshold cycle method. Triplicate
Ct values were averaged, and the relative expression
levels of the four ESCC cell lines were determined as 2−ΔCt
(ΔCt = Ct miR-34a in ESCC tissues −Ct RNU6 gene in normal tissues).
Statistical analysis
Data were analyzed in GraphPad Prism 5.0 (GraphPad
Software Inc., San Diego, CA, USA) and SPSS 13.0 (SPSS
Inc., Chicago, IL, USA). All P values were two-sided,
and the significance level was P < 0.05. A Mann–Whitney
U-test was performed to compare the miR-34a methyla-
tion levels of every CpG site between the ESCC and
control groups and between male and female subjects.
The association between each CpG site methylation
of miR-34a and the clinicopathologic parameters was
Figure 1 (See legend on next page.)
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Figure 1 Genomic structure of distribution of miR-34a CpG dinucleotides over transcription start site (TSS) and hierarchical cluster
analysis of CpG units’ methylation profiles of miR-34a promoter region in tumor (n = 59) and normal (n = 34) tissues. The depicted
region corresponds to 1.2 kbp upstream of the TSS (indicated by arrow). Each vertex indicates an individual CpG site. The positions and
orientation of the MassARRAY primers are indicated by horizontal black bars. The position of the p53 binding site is indicated. Columns display
the clustering of CpG units, which are a single CpG site or a combination of CpG sites. Each row represents a sample. The methylation intensity
of each miR-34a CpG unit in each sample varies from red to black, which represents high to low expression. The color gradient between black
and red indicates methylation ranging from 0 to 100. Gray represents technically inadequate or missing data.
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U-test between two groups and the Kruskal–Wallis
H test for three or more groups). Spearman correlation
was analyzed to evaluate the correlations between
the CpG site methylation level of miR-34a and its
expression levels. Two-sample t-tests were conducted
to compare the miR-34a expression between ESCC and
normal tissues.
Results
Hypermethylation of miR-34a promoter in Kazakh patients
with ESCC
The MassARRAY system is a tool for the high-throughput
detection and quantitative analysis of methylation at a
single CpG site at a target fragment (CpG island) that gen-
erates accurate data that represent the ratio or frequency
of methylation events on a CpG site by MALDI-TOF MS.
This system was used to assess the methylation profile of
miR-34a in all the samples collected from Kazakh patients
with ESCC (n =59) and from control subjects (n = 34).
The amplicon detected in the promoter regions of
miR-34a was 318 base pairs in length (proximal region
encompassing the transcription start site and the p53
binding sites) and contained 23 CpG sites that can be
divided into 15 CpG units.
Among these CpG units, four CpG units (7 CpG sites)
yield unsuccessful measurements. The final dataset con-
sisted of 11 CpG units (2,139 sites in 93 analyzed samples),
and the individual CpG unit methylation of miR-34a that
distinguished ESCC from normal tissues is depicted in the
cluster diagram (Figure 1). The patterns observed inTable 1 Sequences of PCR primers used in this study
Gene Primer Sequence(5′-3′) Product size (bp)
miR-34a tag-FW 5′ -aggaagagagGTTTATTTG
GGTGTATGTTGGGA-3′
318
T7-RV 5′-cagtaatacgactcactataggga
gaaggctACCTAATCCTCTTTC
CTTTTCAAAT-3′
β-globin For 5′-CAGACACCATGGTGCAC
CTGAC-3′
210
Rev 5′-CCAATAGGCAGAGAGAGT
CAGTG-3′
“FW”: Forward, “RV”: Reverse.the cluster analyses show that the methylation status of
normal controls was notably different from that observed
in tumor tissues. The overall methylation level of the tar-
get fragment of the miR-34a promoter was statistically
higher (0.133 ± 0.040) in Kazakh esophageal cancer than
in normal tissues (0.066 ± 0.045, P < 0.01, Figure 2A). The
methylation level of every CpG unit within the miR-34a
promoter was also evaluated (Figure 2B). Apart from
that CpG_23, the mean methylation levels at CpG_1.2,
CpG_3, CpG_4, CpG_5, CpG_6, CpG_8.9, CpG_14.15.16,
CpG_17.18, CpG_19 and CpG_20 were all significantly
higher in patients with ESCC (mean methylation = 28.75%,
16.25%, 8.00%, 10.50%, 10.00%, 15.25%, 8.00%, 4.75%,
17.25%, 19.25%, respectively) than in the controls(mean
methylation = 18.25%, 12.00%, 4.25%, 5.75%, 3.75%, 4.50%,
4.75%, 1.25%, 4.75%, 6.50%, respectively; all the P values
are less than 0.01).
Hypermethylated miR-34a in esophageal carcinoma is
associated with metastasis development
The association between the patterns of the quantitative
methylation of every CpG unit within the miR-34a pro-
moter and the clinicopathologic features of the 59 Kazakh
patients with ESCC was further evaluated (Table 2). The
CpG_5 and CpG_8.9 methylation levels of miR-34a in
lymph node metastasis tumor tissue were remarkably
greater than those in tumor tissue without lymph node
metastasis (10.9% vs. 6.9%, p = 0.026; 16.4% vs. 12.1%,
p = 0.022, respectively; two-tailed Mann–Whitney U-test).
The CpG_8.9 methylation levels of miR-34a in tumor-stage
III/IV tissues were also significantly higher than those
stage I/II tissues (17.0% vs. 13.9%, P = 0.029; two-tailed
Mann–Whitney U-test, Figure 3). However, no correlation
was found between the other CpG units methylation of
miR-34a and age at diagnosis, gender, and tumor differen-
tiation of Kazakh ESCC.
Suppresion of miR-34a in Kazakh ESCC tissue
To determine whether CpG methylation is accompanied by
decreased miR-34a expression, we examined expression of
miR-34a mRNA by real-time PCR in the same cohort
(tumor n = 59; normal n = 34) used for the methylation
analysis. The results, consistent with our expectation,
indicated that the miR-34a gene showed a nearly two-fold
Figure 2 Evaluation of promoter methylation of miR-34a. (A) Comparison of average methylation status of miR-34a promoter between
control and ESCC subjects. (B) Median methylation levels of 11 informative CpG units in miR-34a promoter between control and ESCC subjects.
**P < 0.01, ***P < 0.001 (Mann–Whitney U-test).
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high level of methylation compared with that in nor-
mal tissues (0.079 ± 0.094 vs. 0.277 ± 0.045, P < 0.0001;
Figure 4).
Correlation between promoter methylation and expression
of miR-34a
We analyzed the Spearman correlation between the
methylation levels at individual CpG units and their ex-
pression. This analysis yielded 11 correlation coefficients
[range: (−0.705) to (+0.263)] (Figure 5A). Notably, a sig-
nificant inverse correlation was observed for CpG_4,
CpG_6, CpG_8.9, CpG_14.15.16, CpG_19, and CpG_20Table 2 Association between miR-34a promoter methylation
CpG unit CpG site C
Gender¶ Age¶ Tumor loca
Unit1 CpG_1.2 −1.396 0.163 −0.364 0.716 −1.227 0
Unit2 CpG_3 −1.075 0.282 −0.259 0.796 −1.592 0
Unit3 CpG_4 −1.558 0.119 −0.457 0.648 −1.359 0
Unit4 CpG_5 −0.039 0.969 −0.528 0.598 −0.607 0
Unit5 CpG_6 −0.168 0.866 −0.330 0.741 −1.057 0
Unit7 CpG_8.9 −0.450 0.653 −0.076 0.939 −0.093 0
Unit9 CpG_14.15.16 −1.429 0.153 −0.360 0.719 −0.891 0
Unit10 CpG_17.18 −0.086 0.931 −0.770 0.441 −0.160 0
Unit11 CpG_19 −0.211 0.833 −0.459 0.646 −0.397 0
Unit12 CpG_20 −0.382 0.702 −0.692 0.489 −0.559 0
Unit15 CpG_23 −0.128 0.898 −0.460 0.646 −1.696 0
Note: ¶Mann–Whitney U test (two-sided); #Kruskal-Wallis H test (two-sided); *P < 0.0methylation and miR-34a expression (Figure 5B and
Table 3). A negative relationship between global miR-34a
methylation and mRNA expression was also observed in
relation to the overall methylation status of the miR-34a
promoter and gene expression (r = −0.594, P = 0.042).
These results demonstrated that the hypermethylation of
the miR-34a promoter region might be the reason for the
suppression of mRNA in Kazakh ESCC tissues.
Discussion
MiRNAs is an important regulator of protein post-
transcriptional regulation in a sequence-specific manner.
MiR-34a is the direct transcriptional targets of p53. Asand clinicopathologic features in ESCC patients
linical characteristic (Z/P)
tion¶ Differentiation# Lymphatic metastasis¶ TNM stage¶
.220 0.334 0.846 −0.628 0.530 −0.838 0.402
.057 5.813 0.055 −0.397 0.691 −1.440 0.150
.174 2.136 0.344 −0.708 0.479 −1.019 0.308
.544 1.901 0.386 −2.223 0.026* −0.625 0.532
.291 2.992 0.224 −1.551 0.121 −0.732 0.464
.926 2.221 0.896 −2.299 0.022* −2.188 0.029*
.373 1.940 0.379 −0.029 0.976 −0.092 0.926
.873 2.183 0.336 −0.612 0.541 −4.70 0.638
.691 0.225 0.893 −0.328 0.743 −0.967 0.334
.576 0.137 0.934 −0.328 0.743 −1.077 0.282
.090 0.735 0.692 −0.711 0.477 −0.174 0.862
5, bold face representing significant data.
Figure 3 Association between miR-34a methylation level and clinicopathologic features in ESCC patients (Mann–Whitney U-test).
(A) Tumors with lymph node metastasis (N1) and without (N0). (B) TNM stage. *P < 0.05.
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apoptosis and a cell cycle arrest in the G1-phase and
targets Notch, HMGA2, and Bcl-2 genes involved in the
self-renewal and survival of cancer stem cells, thereby
suppressing tumor cell proliferation, which is dysregu-
lated in many cancers [26]. MiR-34a is hypermethylated
in non-small-cell lung cancer (64%, 20/31), melanoma
(62.5%, 20/32), and prost ate carcinoma (79.1%, 19/24)
[22,27]. In contrast to the regulation of other miRNAs,
miR-34a regulation in esophageal cancer is only par-
tially understood. Studies of the methylation levelsFigure 4 Average relative miR-34a expression level in ESCC compared
miR-34a was measured by qRT-PCR and was normalized by U6RNA. Each s
represent the standard error of mean, and asterisks represent a statisticallyof the region 100 to 500 base-pairs upstream of the
miR-34a transcription start, which includes the p53
binding site, in the prostate and pancreas carcinoma
cell lines, such as LNCaP, PC-3, LAPC-4 and TsuPr1,
have shown a significant correlation between the silen-
cing of miR-34a expression and the levels of CpG
methylation of the region 400 base-pairs promoter re-
gion of the miR-34a, which includes the p53 binding
site [22]. In the present study, we examined the same
region in the esophageal tissues and quantitatively de-
tected the methylation patter by MALDI -TOF masswith that in normal esophageal tissues. The expression level of
ample was analyzed in triplicate, repeated three times. Error bars
significant difference (P < 0.0001).
Figure 5 Negative correlation of miR-34a specific CpG units’ methylation and their expression. (A) Bar plot of Spearman correlation
coefficient (r) showing strength of negative correlation between miR-34a expression and methylation value of each CpG unit within miR-34a, with
negative values representing inverse correlations and positive values representing positive correlations. Significant correlations (P < 0.05) are
indicated in red. (B) Analysis of scatterplots and simple linear regression graphically displaying the correlation between methylation level of each
CpG unit and miR-34a gene expression in Kazakh ESCC samples by Spearman correlation coefficient analysis. The straight line was the “best fit”
that indicated the trend of relationship.
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was frequently methylated in esophageal cancer and its
methylation was related to loss of miR-34a expression.
These results suggest that aberrant promoter methylation
plays an important role in the down-regulation of
miR-34a gene expression in Kazakh patients with esopha-
geal cancer.Table 3 Correlation analysis of DNA methylation of
individual CpG sites and miR-34a mRNA expression in
Kazakh ESCC patients
CpG unit CpG site Spearman’s correlation
coefficient
P value
Unit1 CpG_1.2 −0.113 0.713
Unit2 CpG_3 0.253 0.363
Unit3 CpG_4 −0.705 0.005
Unit4 CpG_5 0.059 0.834
Unit5 CpG_6 −0.597 0.019
Unit7 CpG_8.9 −0.545 0.036
Unit9 CpG_14.15.16 −0.552 0.033
Unit10 CpG_17.18 −0.259 0.372
Unit11 CpG_19 −0.606 0.017
Unit12 CpG_20 −0.606 0.017
Unit15 CpG_23 −0.324 0.28
P values correspond to two-sided Spearman correlation tests.DNA methylation acts as an important switch that
controls gene expression in cancer where methylation
exhibits tumor-specific patterns [10]. To date, various
ESCC-susceptible genes with aberrant DNA methylation
or gene expression have been identified, such as RASSF1A
genes [13]. miRNAs considerablely affects the initiation
and progression of human cancers and therefore represent
promising targets for anticancer therapies. Patterns of
aberrant miRNA expression are involved in ESCC, and
miRNA acts as oncogenes or tumor suppressors [28,29].
In the present study, we successfully replicated the results
of the study by Chen et al. in the Chinese Han population
by the traditional method [30], methylation-specific PCR
(MSP), not the quantitative method, although the par-
ticipants in both studies had different genetic and envir-
onmental backgrounds. The research conducted by Chen
et al. have found that the methylation ratio of miR-34a
is 66.7% (36/54) in ESCC patients from Chinese Han
population, which are significantly higher than that in the
corresponding non-tumor tissues [30]. However, previous
studies have identified ethnic variations in DNA methy-
lation levels related to lifestyle and dietary differences
[31]. Consequence, with non-quantitative MSP method in
Chinese Han population and the quantitative MassARRAY
approach in Kazakh population, the uniformity of the
methylation of the miR-34a promoter in both studies
strengthens the association between such methylation
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in numerous cancers, including colorectal, pancreatic,
mammary, ovarian, urothelial, renal cell carcinomas,
and soft tissue sarcomas [22,32], the finding presented
here is the first to demonstrate the suppression of
miR-34a via promoter methylation in Kazakh patients
with esophageal cancer.
Epidemiological and etiological studies have shown
that the carcinogenesis and development of ESCC involves
multiple factors and changes in gene expression [2,33-36].
Recent data suggest that dysregulation of miR-34a exists
in various types of human cancers and is associated with
clinic treatment [22,23,26,27,32,37,38]. Here, we found
that miR-34a, direct transcriptional targets of the p53,
showed a nearly two-fold elevated expression in nor-
mal esophageal tissues compared with that in tissues of
Kazakh patients with esophageal cancer, in accordance
with the results in a study by Hu [24]. Moreover, miR-34a
mRNA expression is inversely correlated with the
methyaltion of the miR-34a promoter, as reported by
Chen et al., confirming the likely role of methylation in
the regulation of miR-34a expression [30]. It is generally
recognized that promoter methylation blocks transcrip-
tion and mRNA expression by preventing binding of
transcription factor. In our results, the promoter region
of the miR-34a contains multiple CpG islands and sites
[22], but the negative correlation between the quantitative
hypermethylation level of each CpG sites and the expres-
sion was observed only in certain CpG sites. The results
indicates that multiple CpG sites, and not methylation of
every site down-regulated or suppressed gene expression.
Only several CpG sites performed genetic transcription,
and the methylated sites were the key CpG sites, perhaps
the most remarkable finding of the present study.
Previous studies have demonstrated that miR-34a is a
direct target of p53, our study revealed a novel mechanism
for miR-34a regulation in Kazakh ESCC. Recently, there
is growing evidence that p53 abnormality is not always
associated with the down-regulation of miR-34a in hu-
man cancer tissues, although several groups have shown
that the well-known tumour suppressive activity of p53
is at least in part moderated by miR-34a [19,20,39,40].
The expression of p53 resulted in up-regulation of miR-34a
in the lung cancer cell line H1299 and the overexpression
of miR-34a suppressed proliferation of lung cancer cells
in vitro and promoted apoptosis [39]. Deletion or muta-
tion of p53 is associated with miR-34a down-regulation
in chronic lymphocytic leukemia and ovarian cancers
[27,41,42]. While in neuroblastoma and small-cell lung
cancer, no significant correlation between p53 mutation
and miR-34a dysregulation is observed [43,44]. However,
there was no direct correlation between the deletion or
mutation of p53 and miR-34a expression levels in ESCC
samples. Like other malignancies, mutations of p53 arecommon molecular genetic events in 60.6% of ESCC
[9]. The observation of aberrant methylation of miR-34a-
induced inactivation raises an important regulation mech-
anism for miR-34a in the etiology of Kazakh ESCC. It has
been hypothesized that miR-34a promoter methylation
preferentially occurs in tumors expressing mutant-type
p53 in esophageal carcinoma. Clearly, future studies are
required to obtain a more complete understanding of
the consequence of miR-34a delivery to ESCC cells with
mutant-type p53.
Our data show the significant correlation of two CpG
sites’ methylation of miR-34a promoter with lymph node
metastasis of Kazakh patients with esophageal carcinoma
and thus suggest that miR-34a is an effective prognostic
marker. This observation is in good agreement with the
report that the methylation of miR-34 promoter is corre-
lated with the metastatic potential of tumor cells, such
as SIHN-011B, osteosarcoma and breast cancer cells lines
[37,38,45], but not accordance with the results from Chen
et al. [30]. Moreover, we analyzed the each CpG site’s
methylation level of miR-34a and lymph node metastasis
in esophageal carcinoma, but a significant correlation
between them was observed only on two CpG sites,
indicating that the overall methylation level cannot
represent the clinical value. Therefore, only the accurate
information of CpG sits’ methylation levels represents the
clinical application value. However, the exact mechanism
for the function of miR-34a epigenetic silencing in metas-
tasis formation remains unambiguous. P53 was found to
modulate miR-34a expression. Several studies have suc-
cessfully discovered target genes of miR-34a involved the
invasion and metastasis in many tumors. Molecularly,
miR-34a suppresses breast cancer invasion and metastasis
by directly targeting Fra-1 and inhibits the metastasis of
osteosarcoma cells by repressing the expression of CD44
[37,38]. An ectopic expression of miR-34a in IMR90 cells
substantially inhibits growth. However, no study on the
miR-34a-targeted gene in ESCC has explained why
miRNA promotes the metastasis. Therefore, the biological
function of the higher rates of miR-34a promoter methyla-
tion in Kazakh ESCC should be further analyzed to clarify
this point.
Conclusions
Our findings not only for the first time demonstrate that
miR-34a CpG island hypermethylation-mediated silencing
of miR-34a with tumor suppressor features contributes to
esophageal carcinoma in Kazakh population but also show
that particular DNA methylation signatures of miR-34a
CpG sites are associated with the metastatic of esophageal
carcinoma. One application is that it is a potential
methylation biomarker for the early diagnosis of esopha-
geal carcinoma and the prediction of metastatic behavior.
Most importantly, miR-34a may provide a mechanistic
Cui et al. Journal of Experimental & Clinical Cancer Research 2014, 33:20 Page 10 of 11
http://www.jeccr.com/content/33/1/20and molecular basis for the new therapeutic use of
pharmacological compounds with DNA demethylating
activity to treat Kazakh patients with esophageal carcin-
oma or metastatic development.
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Additional file 1: Table S1. The clinicopathological demographics for
the 59 Kazakh patients with ESCC.
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